04 Dec Healthcare Costs in Patients with Cancer Rise with Increasing Risk of Venous Thromboembolism
MedicalResearch.com Interview with:
Dr. Burton
Paul Burton MD, PhD, FACC
Vice President, Medical Affairs
Internal Medicine
Janssen Scientific Affairs, LLC.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Despite being largely preventable, venous thromboembolism (VTE) is the second leading cause of death in people with cancer. The risk of VTE is five times greater in people with cancer than those without cancer, and that risk is magnified in those receiving certain types of chemotherapy, in the newly diagnosed and in those with more advanced, metastatic disease. This 6,194-patient study examined economic burden associated with VTE, and found patients newly diagnosed with cancer who are at a higher risk of a VTE had significantly higher all-cause and VTE-related health care costs compared to patients with a lower risk of VTE.
MedicalResearch.com: What should readers take away from your report?
Response: Management of VTE in patients with cancer remains a high priority in cancer care. People deserve the chance to focus their attention on treating their cancer and getting better, without the concern and burden of VTE, which is associated with high mortality rates and health care costs.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: It is important that we continue to examine the management of venous thromboembolism in patients with cancer. That’s why we initiated the CALLISTO research program, which is the largest and broadest prospective clinical program evaluating a Factor Xa inhibitor, specifically XARELTO®, for the prevention and treatment of cancer-associated VTE. It includes clinical trials and registries in more than 4,000 patients.
MedicalResearch.com: Is there anything else you would like to add?
Response: Currently, XARELTO® (rivaroxaban) is indicated for the treatment and secondary prevention of VTE in people with cancer. At this year’s ASH meeting, we also presented late-breaking results from our Phase 3b CASSINI study, which examined XARELTO® for the primary prevention of VTE in high-risk cancer patients. The composite primary endpoint of VTE occurrence did not reach statistical significance during the full study period. However, use of XARELTO® resulted in a clinically meaningful and nominally significant 60 percent reduction of VTE events compared to placebo during the time patients were actively receiving treatment. Bleeding rates were low, though higher with XARELTO®. CASSINI is a part of our CALLISTO program and adds to the robust research from our prior XARELTO® trials.
Citation:
Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism
Monday, December 3, 2018, 6:00 PM-8:00 PM
Michael B. Streiff, MD1, Keith R. McCrae, MD2, Nicole M. Kuderer3, Dejan Milentijevic, PhD4*, Guillaume Germain, MA5*, François Laliberté, MA5*, Nguyen Le, BSc6*, Patrick Lefebvre, MA7*, Gary H. Lyman8 and Alok A. Khorana9
1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3University of Washington, Seattle, WA
4Janssen Scientific Affairs, LLC, Titusville, NJ
5Groupe d’analyse, Ltée, Montréal, QC, Canada
6Analysis Group, Inc., Boston
7Analysis Group, Inc, Montreal, QC, Canada
8Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA
9Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
[wysija_form id=”3″]
[last-modified]
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on December 4, 2018 by Marie Benz MD FAAD